Replies to post #224721 on Biotech Values

[DewDiligence]

RVNC has stated on numerous occasions that the in-house manufacturing capacity is sufficient for commercial as well as clinical volumes.

The underlying premise of the MYL partnership on a Botox biosimilar is that RVNC has more manufacturing capacity than needed.

[jbog]

mounton29,

Their 10-K makes it sound like their internal capacity goes beyond clincial trials.

When dealing with these toxins you have to really read their description carefully.

Revance has plenty of production to produce the original active ingredient which is a purified toxin. How much can they produce? My guess would be around a half of gram per year or so. As a side note, I don't believe Allergan has ever used more than a gram per year.

To describe how toxic this is is there's an estimation that one 13 billionth of a gram inhaled will kill the average human.

The mass of this item is less than the size of a baby aspirin.

That's the product's bulk production.

Then this has to go to a finish fill operation. That's where this bulk product is added to other inactive ingredients and diluted many times over to get it to an manageable potency. After this is accomplished you then have to turn a vial of this super diluted liquid back into a solid form through sublimation.

As you can see, if you made enough bulk material about the size of a speck of dust you'd have enough active ingredients for thousands and thousands of injections.